Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2021 | Comprehensive genomic profiling

Umberto Malapelle • 18 Oct 2021
ISLB 2021
Lung Cancer

Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, outlines the advantages of comprehensive genomic profiling (a combination of next generation sequencing and liquid biopsy). This technique is effective for detecting a range of mutations and gene alterations at the same time, which allows for faster diagnosis for patients. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.

Disclosures

Speaker’s bureau for Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS, Thermofisher, Biocartis.

Advisory role for Boehringer Ingelheim, MSD, Amgen, Merck, BMS, Diaceutics, Roche, Eli Lilly, Thermofisher, Janssen.

More from Umberto Malapelle

0:54
Liquid biopsy highlights from ELCC 2023
Umberto Malapelle • 27 Mar 2023
1:46
ctDNA approaches in lung cancer
Umberto Malapelle • 27 Mar 2023
1:23
Optimal positioning of liquid biopsies in the workup of patients with NSCLC
Umberto Malapelle • 27 Mar 2023
1:57
Potential of liquid biopsy in lung cancer
Umberto Malapelle • 18 Oct 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals